|
|
|
05.06.26 - 14:54
|
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology. (GlobeNewswire EN)
|
|
|
MIAMI, June 05, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq:NRXP, “the Company”) announces the presentation of a peer-reviewed poster at the 2026 American Society of Clinical Psychopharmacology annual conference documenting Real World Evidence of effectiveness associated with the use of intravenous (IV) ketamine to treat depression compared to intranasal esketamine. The presentation, entitled “Real World Evidence of Clinical Treatment Response Following Intravenous Racemic Ketamine Versus Intranasal Esketamine in Adults with Major Depressive Disorder” was jointly authored by Robert Dougherty, Emily Shih, Jamie Lo, and Jimmy Qian of Osmind, Inc., and Prof. Samuel Wilkinson, MD, of Yale University Department of Psychiatry....
|
|
|
04.06.26 - 23:15
|
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters′ Option (GlobeNewswire EN)
|
|
|
Offering was led by B Group Capital with significant participation from, among others, Columbia Threadneedle Investments, Corbets Capital, Venture 76, and Mossrock Capital Offering was led by B Group Capital with significant participation from, among others, Columbia Threadneedle Investments, Corbets Capital, Venture 76, and Mossrock Capital...
|
|
|
|
|
03.06.26 - 14:21
|
NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock (GlobeNewswire EN)
|
|
|
WILMINGTON, Del., June 03, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering (the “Offering”) of 5,714,286 shares of its common stock, par value $0.001 per share (“Common Stock”) at a public offering price of $3.50 per share of Common Stock....
|
|
|
|
|
|
|
02.06.26 - 22:03
|
NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire EN)
|
|
|
WILMINGTON, Del., June 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it intends to offer shares of its common stock, par value $0.001 per share (“Common Stock”) in an underwritten public offering (the “Offering”). The Company also expects to grant to the underwriter of the Offering a 30-day option to purchase up to an additional 15% of the shares of Common Stock sold in the Offering on the same terms and conditions. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed or as to the actual size or terms of the Offering....
|
|
|
28.05.26 - 13:03
|
NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026 (GlobeNewswire EN)
|
|
|
SARASOTA, Fla. and PARIS, May 28, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) today announced that its strategic partner, Emobot Health, presented a late-breaking poster at the 2026 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP), reporting the first pooled clinical validation of EMOCARE, the investigational passive, multimodal, smartphone-based “Depression Thermometer” that powers the Emobot app now being deployed across the Hope Therapeutics network of interventional psychiatry clinics....
|
|
|
|
|
|
|
|
|
|
|
16.05.26 - 13:06
|
New to The Street′s Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast, Stardust Power, Lost Soldier Oil and Gas, Virtuix Holdings, and Medicus Pharma (Accesswire)
|
|
|
The show broadcasts as sponsored programming featuring TV commercials from IGC Pharma, Inc. (NYSE American:IGC), NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), Medicus Pharma Ltd. (NASDAQ:MDCX), and Data......
|
|
|
|
|
|
|
14.05.26 - 13:06
|
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update (GlobeNewswire EN)
|
|
|
WILMINGTON, Del., May 14, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that it will release its first quarter 2026 financial results before the market opens on Monday, May 18, 2026 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call at 8:00am ET the same day....
|
|
|
|
|
|
|
15.04.26 - 13:03
|
NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications (GlobeNewswire EN)
|
|
|
MIAMI, April 15, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related conditions, today announces the incorporation of NRx Defense Systems, Inc., a Florida-based Research and Development subsidiary. The subsidiary is charged with development of neuroplastic treatments that combine D-cycloserine with Transcranial Magnetic Stimulation (TMS) under robotic-enabled neuro-navigation, using already developed technology. The Company anticipates participating in future government and non-governmental research and development on a basis that is non-dilutive to current shareholders....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
